Table 6. Incidence of New Vertebral Fractures and Adverse Events: Randomized controlled Trials of Percutaneous Vertebroplasty for Treatment of Osteoporotic Vertebral Fractures.

Study	New Vertebral Fracture N	Adverse Events N
Liu et al. 2010	Within 2 months PV: 0 BK: 2 adjacent	NR
Kallmes et al. 2009(7)	NR	PV: 1 injury to the thecal sac during The procedure which required hospitalization CI: 1 tachycardia
Buchbinder et al. 2009(8)	Within 6 months: PV: 3 CI: 4	Chest pain: PV: 3 CI: 0 Pain or burning in thigh or leg: PV: 4 CI: 2 Increased pain or muscle cramping around puncture site: PV: 2 CI: 1 Minimal leakage reported in 14 (37%) Osteomyelitis in a patients who did not receive cephalothin due to multiple drug allergies
Rousing et al. 2009(9) & 2010(13)	Within 3 months: PV: 3; 2 were adjacent CI: 1; not adjacent RR for all new VCFs, 2.9 (95% CI, 0.3-25.7) After 3 months and up to 12 months: PV: 4; 1 adjacent CI: 3, non adjacent RR for all new VCFs after 12 months, 1.3	Extravertebral cement leakages following PV
Voormolen et al. 2007(10)	PV: 2 adjacent VCF CI: 0	PV: 1 pedicle chip due to PV (but crossed over from CI)

PV, Percutaneous vertebroplasty; CI, Control intervention